"Designing Growth Strategies is in our DNA"

U.S. Orphan Drugs Market Size, Share, Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, and Others), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2024-2032

Last Updated: February 24, 2025 | Format: PDF | Report ID: FBI108225

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Rare Diseases in the U.S., 2022/2023
    2. Pipeline Analysis, By Key Players
    3. New Product Launches, By Key Players
    4. Key Industry Developments: Mergers, Acquisitions & Partnerships
    5. Technological Developments
    6. Impact of COVID-19 on the Market
  5. U.S. Orphan Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Therapy Area
      1. Oncology
      2. Hematology
      3. Neurology
      4. Endocrinology
      5. Cardiovascular
      6. Respiratory
      7. Immunotherapy
      8. Others
    2. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-Biologics
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Amgen Inc. (U.S.)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Bayer AG (Germany)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. F. Hoffmann-La Roche Ltd (Switzerland)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Alexion Pharmaceuticals Inc. (U.S.)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Novo Nordisk A/S (Denmark)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Novartis AG (Switzerland)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Bristol-Myers Squibb Company (U.S.)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. AstraZeneca (U.K.)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. DAIICHI SANKYO COMPANY, LIMITED (Japan)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. GlaxoSmithKline plc (U.K.)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      11. Other Prominent Players

 

Read Less

Figure 1: U.S. Orphan Drugs Market Revenue Breakdown (USD billion, %) by Drug Type, 2024 & 2032

Figure 2: U.S. Orphan Drugs Market Value Share (%), by Therapy Area, 2024 & 2032

Figure 3: U.S. Orphan Drugs Market Value Share (%), by Drug Type, 2024 & 2032

Figure 4: U.S. Orphan Drugs Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 5: U.S. Orphan Drugs Market Share (%), By Company, 2023

Table 1: U.S. Orphan Drugs Market Revenue (USD billion) Forecast, by Therapy Area, 2019–2032

Table 2: U.S. Orphan Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2019–2032

Table 3: U.S. Orphan Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

U.S. Orphan Drugs Market Size, Share and Global Industry Trend Forecast till 2032
  • 2019-2032
  • 2023
  • 2019-2022
  • 70
Consulting Services
    How will you benefit from our consulting services ?